6 News & Press Releases found
Avelas Biosciences News
-
Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program
Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22 SAN DIEGO, CA – ...
-
Avelas Biosciences Presents Phase 2, Period 2 Data in Virtual Poster Session at the 22nd Annual Meeting of The American Society of Breast Surgeons
SAN DIEGO, CA – Avelas Biosciences, Inc., a pioneer in the field of fluorescence imaging for real-time cancer detection, presented the results from Period 2 of its most recent clinical trial in a virtual poster session at the 22nd Annual ...
-
Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery
SAN DIEGO, CA – Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration ...
-
Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer Surgery
Use of pegloprastide, a fluorescent cancer marker, during surgery correctly identified cancer in up to 75% of patients who may have otherwise been candidates for a repeat (re-excision) surgery Observed re-excision rate was ~6% in patients whose ...
-
Avelas Welcomes Susan Stimson to its Board of Directors
SAN DIEGO, November 22, 2019 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection is pleased to announced the addition of Susan Stimson as a Director of the company. ...
-
Avelas Biosciences Presents Phase II, Period 1 Data in Poster Session at San Antonio Breast Cancer Symposium
SAN DIEGO, December 4, 2018 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection, presented the initial results of the first part of its Phase II clinical trial in a poster ...